Dolphimed A/S

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 28.0% 18.1% 12.3%  
Credit score (0-100)  0 0 1 7 19  
Credit rating  N/A N/A B B BB  
Credit limit (kDKK)  0.0 0.0 -0.0 -0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 -15,475 -1,932 -163  
EBITDA  0.0 0.0 -16,525 -1,933 -163  
EBIT  0.0 0.0 -16,988 -2,627 -858  
Pre-tax profit (PTP)  0.0 0.0 -20,130.7 -6,435.1 -5,168.9  
Net earnings  0.0 0.0 -20,130.7 -6,435.1 -5,168.9  
Pre-tax profit without non-rec. items  0.0 0.0 -20,131 -6,435 -5,169  

 
See the entire income statement

Balance sheet (kDKK) 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 0.0 -19,731 -26,166 -31,335  
Interest-bearing liabilities  0.0 0.0 16,132 17,745 19,520  
Balance sheet total (assets)  0.0 0.0 23,179 16,994 16,106  

Net Debt  0.0 0.0 10,407 16,972 19,351  
 
See the entire balance sheet

Volume 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 -15,475 -1,932 -163  
Gross profit growth  0.0% 0.0% 0.0% 87.5% 91.5%  
Employees  0 0 1 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 23,179 16,994 16,106  
Balance sheet change%  0.0% 0.0% 0.0% -26.7% -5.2%  
Added value  0.0 0.0 -16,525.3 -2,164.0 -163.4  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 16,432 -1,389 -1,389  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 -1.0 -2.0 -3.0  

Profitability 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 109.8% 136.0% 525.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% -39.2% -5.7% -1.9%  
ROI %  0.0% 0.0% -42.9% -6.0% -1.9%  
ROE %  0.0% 0.0% -86.8% -32.0% -31.2%  

Solidity 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  0.0% 0.0% -46.0% -60.6% -66.1%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% -63.0% -878.2% -11,845.0%  
Gearing %  0.0% 0.0% -81.8% -67.8% -62.3%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 41.2% 23.4% 23.2%  

Liquidity 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  0.0 0.0 1.7 24.1 1,261.3  
Current Ratio  0.0 0.0 1.7 24.1 1,261.3  
Cash and cash equivalent  0.0 0.0 5,725.4 773.4 168.5  

Capital use efficiency 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 2,580.6 760.5 598.6  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 -16,525 -2,164 -163  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 -16,525 -1,933 -163  
EBIT / employee  0 0 -16,988 -2,627 -858  
Net earnings / employee  0 0 -20,131 -6,435 -5,169